CY1106992T1 - Καχαλαλιδη f και συναφεις ενωσεις - Google Patents

Καχαλαλιδη f και συναφεις ενωσεις

Info

Publication number
CY1106992T1
CY1106992T1 CY20071101442T CY071101442T CY1106992T1 CY 1106992 T1 CY1106992 T1 CY 1106992T1 CY 20071101442 T CY20071101442 T CY 20071101442T CY 071101442 T CY071101442 T CY 071101442T CY 1106992 T1 CY1106992 T1 CY 1106992T1
Authority
CY
Cyprus
Prior art keywords
walnut
related compounds
cachalide
preparation
results
Prior art date
Application number
CY20071101442T
Other languages
Greek (el)
English (en)
Inventor
Fernando Albericio
Ernest Giralt
Jose Carlos Jimenez
Angel Lopez
Ignacio Manzanares
Ignacio Rodrigues
Miriam Royo
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of CY1106992T1 publication Critical patent/CY1106992T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
CY20071101442T 2000-02-09 2007-11-08 Καχαλαλιδη f και συναφεις ενωσεις CY1106992T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
EP01904169A EP1254162B1 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds

Publications (1)

Publication Number Publication Date
CY1106992T1 true CY1106992T1 (el) 2012-09-26

Family

ID=9885232

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101442T CY1106992T1 (el) 2000-02-09 2007-11-08 Καχαλαλιδη f και συναφεις ενωσεις

Country Status (27)

Country Link
US (2) US7482429B2 (https=)
EP (3) EP1829889A3 (https=)
JP (1) JP5188665B2 (https=)
KR (1) KR100871489B1 (https=)
CN (2) CN101597326B (https=)
AT (1) ATE371667T1 (https=)
AU (1) AU783542B2 (https=)
BG (1) BG65926B1 (https=)
BR (1) BR0108213A (https=)
CA (1) CA2399187C (https=)
CY (1) CY1106992T1 (https=)
CZ (1) CZ304258B6 (https=)
DE (1) DE60130192T2 (https=)
DK (1) DK1254162T3 (https=)
ES (1) ES2292558T3 (https=)
GB (1) GB0002952D0 (https=)
HU (1) HUP0301817A3 (https=)
IL (2) IL150981A0 (https=)
MX (1) MXPA02007760A (https=)
NO (1) NO331847B1 (https=)
NZ (1) NZ520488A (https=)
PL (1) PL207121B1 (https=)
PT (1) PT1254162E (https=)
RU (1) RU2280039C2 (https=)
SK (1) SK11242002A3 (https=)
UA (1) UA76949C2 (https=)
WO (1) WO2001058934A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
WO2009052379A2 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
EP2262522A1 (en) * 2008-03-07 2010-12-22 Pharma Mar, S.A. Improved antitumoral treatments
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
IL314441A (en) 2022-04-21 2024-09-01 Zevra Therapeutics Inc Gamma-Hydroxybutyrate providing compounds and processes for their production and use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
CA2100745C (en) * 1991-11-19 2007-07-31 Laura S. L. Gaeta Amylin agonist peptides and uses therefor
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7476198A (en) * 1997-05-09 1998-11-27 General Hospital Corporation, The Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7056502B2 (en) * 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
NZ525243A (en) 2000-10-31 2005-01-28 Pharma Mar S A lyophilised formulation comprising kahalalide F, a peptide isolated from a herbivorous marine species of mollusc, Elysia rufescens, to treat cancer
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
CN101597326B (zh) 2014-07-09
US7482429B2 (en) 2009-01-27
DE60130192D1 (de) 2007-10-11
RU2280039C2 (ru) 2006-07-20
IL150981A (en) 2013-05-30
UA76949C2 (en) 2006-10-16
BR0108213A (pt) 2003-03-05
IL150981A0 (en) 2003-02-12
SK11242002A3 (sk) 2003-06-03
AU3208601A (en) 2001-08-20
PL356800A1 (en) 2004-07-12
EP1254162A2 (en) 2002-11-06
KR100871489B1 (ko) 2008-12-05
JP5188665B2 (ja) 2013-04-24
PT1254162E (pt) 2007-12-03
BG65926B1 (bg) 2010-05-31
CN1422278A (zh) 2003-06-04
MXPA02007760A (es) 2002-10-23
JP2003522198A (ja) 2003-07-22
EP1829889A3 (en) 2007-09-26
CN101597326A (zh) 2009-12-09
NZ520488A (en) 2005-03-24
ATE371667T1 (de) 2007-09-15
HK1047290A1 (en) 2003-02-14
NO20023749D0 (no) 2002-08-08
KR20020092951A (ko) 2002-12-12
AU783542B2 (en) 2005-11-10
US20040214755A1 (en) 2004-10-28
CZ20022740A3 (cs) 2003-01-15
GB0002952D0 (en) 2000-03-29
EP1829889A2 (en) 2007-09-05
BG107020A (bg) 2003-05-30
DE60130192T2 (de) 2008-05-21
PL207121B1 (pl) 2010-11-30
RU2002123877A (ru) 2004-01-10
ES2292558T3 (es) 2008-03-16
US20080318849A1 (en) 2008-12-25
DK1254162T3 (da) 2008-01-02
CA2399187C (en) 2011-04-19
EP2258715A1 (en) 2010-12-08
NO331847B1 (no) 2012-04-23
WO2001058934A3 (en) 2002-03-21
CA2399187A1 (en) 2001-08-16
CZ304258B6 (cs) 2014-02-05
HUP0301817A3 (en) 2011-10-28
WO2001058934A2 (en) 2001-08-16
HUP0301817A2 (hu) 2003-09-29
NO20023749L (no) 2002-10-07
EP1254162B1 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
CY1106992T1 (el) Καχαλαλιδη f και συναφεις ενωσεις
CY2012009I2 (el) Αναστολεις της κυκλοπροπυλ-συντηκωμενης διπεπτυλοπεπτιδασης 4, βασισμενοι σε πυρρολιδινη, και μεθοδοι για την παρασκευη των και την χρηση των
CY2018023I2 (el) Ενωσεις υποκατεστημενου κυκλοπεντανιου και κυκλοπεντενιου χρησιμες ως αναστολεις νευραμινιδασης
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
CY2010011I1 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
NO20024562L (no) Seismiske kildegrupper
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1107087T1 (el) Μιμητικα θρομβοποιητινης
ES2182906T3 (es) Grapa quirurgica helicoidal.
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
UY25157A1 (es) Composiciones farmacéuticas conteniendo atorvastatina y amlodipino
DE69714718D1 (de) Akustische quelle ii
TR200100146T2 (tr) Antidepresan etkiye sahip madde
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
NO20024514D0 (no) Kildebölgeformer for elektroseismisk undersökelse
DE69820295D1 (de) Markieren von diamanten oder edelsteinen mittels mehrerer nuten
DE69925333D1 (de) Zur richtigen Ausführung von Heft- und Lochungsoperationen geeignetes Bildformgerät
DE69713169D1 (de) Akustische quelle
DE69019177D1 (de) Akustische Quelle für maritime Zwecke.
DE69831229D1 (de) Schnelle bestimmung des verhältnisses von biologischen molekülen
CY1107039T1 (el) Αναστολεις τριπεπτιδυλ πεπτιδασης
EA200200798A1 (ru) Кальцилитические соединения
DE69930844D1 (de) Inhibitoren von mycobakterien